13 Jun 2022 | 02:45 PM GMT
Past Meeting

Combo DTx-drug: Pharma opportunities

Participants:

Smit Patel Doctor of PharmacyThe Ohio State University
Smit Patel
Doctor of PharmacyThe Ohio State University
Chandana Fitzgerald President, CommunityHLTHOther
Other
Chandana Fitzgerald
President, CommunityHLTH
Anish Shindore Founder & Managing PartnerGSD HealthHealth Tech & Solutions
Health Tech & Solutions
Anish Shindore
Founder & Managing PartnerGSD Health
Anna-Maria Heidinger Head of digital innovation hubDaiichi Sankyo Europe GmbHLife Sciences, Pharma & Biotech
Life Sciences, Pharma & Biotech
Anna-Maria Heidinger
Head of digital innovation hubDaiichi Sankyo Europe GmbH
Brian Mahony Medical Research FellowBioinnovate
Brian Mahony
Medical Research FellowBioinnovate
Caoimhe Vallely-Gilroy Independent Advisor - Pharma & LifesciencesBasel Area, DayOneNon Profit & Academia
Non Profit & Academia
Caoimhe Vallely-Gilroy
Independent Advisor - Pharma & LifesciencesBasel Area, DayOne
Chris Wasden Chief Strategy OfficerTwillOther
Other
Chris Wasden
Chief Strategy OfficerTwill
Emily Lewis Global Digital Transformation LeadUCB
Emily Lewis
Global Digital Transformation LeadUCB
Jaydev Thakkar Chief Operations OfficerBiofourmisOther
Other
Jaydev Thakkar
Chief Operations OfficerBiofourmis
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.Startup
Startup
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Simon Bock Market Access ManagerTiefenbacher PharmaceuticalsLife Sciences, Pharma & Biotech
Life Sciences, Pharma & Biotech
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals
Smit Patel Partnership & Commercial GTM ExecutiveCVS HealthPayer & Insurer
Payer & Insurer
Smit Patel
Partnership & Commercial GTM ExecutiveCVS Health
Tahir Hussain Global Pharma Business Dev. Digital HealthBiofourmisOther
Other
Tahir Hussain
Global Pharma Business Dev. Digital HealthBiofourmis

About this Meeting

DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?  

This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss: 

  • How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?  
  • When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?  
  • Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs? 
  • What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos? 
  • What does the promotion of these combos look like? 

About Us

HLTH Inc. is a dynamic community delivering unique value to the healthcare industry through a mix of unparalleled global events, inspirational content, and impact-driven initiatives.

Hyve Logo

USA Event Dates

2026 | HLTH: Nov 15 – 18 | Las Vegas | Register | Sponsor
2027 | ViVE: Mar 14 – 17 | Nashville | Be First to Know | Sponsor
2027 | HLTH: Oct 17 – 20 | Las Vegas, NV

Europe Event Dates

2027 | HLTH Europe: Jun 21 – 24 | Amsterdam | Sponsor
2028 | HLTH Europe: Jun 19 – 22 | Amsterdam

Important Notice on Hotel Scams

Any communication that claims to represent HLTH or any third party offering discounted hotel rooms or attendee lists is NOT AFFILIATED with HLTH and should be considered fraudulent. Please book your accommodations only through HLTH’s official channels to ensure authenticity and security.